Agilent Technologies (A) announced the launch of Agilent Advanced Therapeutics, a unified contract development and manufacturing organization (CDMO) platform integrating its capabilities across Canada and the United States.

The new platform combines the strengths of BIOVECTRA in Canada and Agilent’s Nucleic Acid Solutions facility in Colorado to provide end-to-end development and manufacturing services for advanced therapeutics.

The offering includes manufacturing and development capabilities for oligonucleotides, microbial fermentation, synthetic chemistry, bioreagents, highly potent APIs and cell line development, enabling customers to move from early discovery through clinical and commercial production with a single partner.